Integra LifeSciences Holdings Co. (NASDAQ:IART) Short Interest Update

Integra LifeSciences Holdings Co. (NASDAQ:IART) was the target of a significant drop in short interest in December. As of December 31st, there was short interest totalling 3,240,000 shares, a drop of 6.1% from the December 15th total of 3,450,000 shares. Based on an average trading volume of 786,000 shares, the days-to-cover ratio is presently 4.1 days. Approximately 4.9% of the shares of the stock are short sold.

Integra LifeSciences Stock Performance

Shares of IART stock opened at $24.10 on Monday. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.20 and a quick ratio of 0.73. Integra LifeSciences has a 12-month low of $16.81 and a 12-month high of $45.42. The business has a 50 day simple moving average of $23.20 and a 200 day simple moving average of $22.41. The firm has a market capitalization of $1.86 billion, a price-to-earnings ratio of -267.75, a price-to-earnings-growth ratio of 0.73 and a beta of 1.16.

Integra LifeSciences (NASDAQ:IART) last released its earnings results on Monday, November 4th. The life sciences company reported $0.41 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.39 by $0.02. Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. The firm had revenue of $380.80 million for the quarter, compared to analyst estimates of $375.81 million. During the same period in the previous year, the company earned $0.76 earnings per share. Integra LifeSciences’s revenue was down .4% compared to the same quarter last year. On average, equities research analysts anticipate that Integra LifeSciences will post 2.45 EPS for the current year.

Insider Activity

In other Integra LifeSciences news, EVP Michael J. Mcbreen sold 1,700 shares of the business’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $24.16, for a total transaction of $41,072.00. Following the transaction, the executive vice president now owns 56,182 shares of the company’s stock, valued at approximately $1,357,357.12. The trade was a 2.94 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 3.10% of the company’s stock.

Institutional Investors Weigh In On Integra LifeSciences

Institutional investors and hedge funds have recently modified their holdings of the business. KBC Group NV boosted its holdings in shares of Integra LifeSciences by 65.2% during the 3rd quarter. KBC Group NV now owns 2,839 shares of the life sciences company’s stock worth $52,000 after buying an additional 1,120 shares during the period. Inspire Investing LLC increased its stake in Integra LifeSciences by 19.0% in the second quarter. Inspire Investing LLC now owns 12,073 shares of the life sciences company’s stock valued at $352,000 after acquiring an additional 1,930 shares during the period. Exchange Traded Concepts LLC lifted its position in shares of Integra LifeSciences by 6.5% during the 3rd quarter. Exchange Traded Concepts LLC now owns 33,403 shares of the life sciences company’s stock worth $607,000 after buying an additional 2,036 shares during the period. New York State Teachers Retirement System increased its position in shares of Integra LifeSciences by 3.0% during the 3rd quarter. New York State Teachers Retirement System now owns 90,098 shares of the life sciences company’s stock worth $1,637,000 after purchasing an additional 2,616 shares in the last quarter. Finally, Nisa Investment Advisors LLC raised its stake in shares of Integra LifeSciences by 599.6% in the fourth quarter. Nisa Investment Advisors LLC now owns 3,267 shares of the life sciences company’s stock valued at $74,000 after acquiring an additional 2,800 shares during the last quarter. Institutional investors and hedge funds own 84.78% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the company. Morgan Stanley initiated coverage on Integra LifeSciences in a research report on Monday, December 2nd. They issued an “underweight” rating and a $20.00 price objective for the company. Truist Financial dropped their price target on shares of Integra LifeSciences from $26.00 to $21.00 and set a “hold” rating for the company in a research note on Monday, October 14th. BTIG Research upgraded Integra LifeSciences from a “sell” rating to a “neutral” rating in a report on Monday, October 7th. Bank of America cut their price target on shares of Integra LifeSciences from $26.00 to $18.00 and set an “underperform” rating on the stock in a research note on Monday, October 7th. Finally, Citigroup raised their price objective on Integra LifeSciences from $16.00 to $22.00 and gave the stock a “sell” rating in a report on Tuesday, November 5th. Three investment analysts have rated the stock with a sell rating, five have assigned a hold rating and one has issued a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $23.00.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.